Redhill Biophrma ADR RDHL

$0.38 -0.01 (-1.60%)

Valuation

Market cap
3,387,000
Revenue TTM
$290,000
Net income TTM
$-430,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-148.28%
Debt to equity
0.00

Trading

Volume
35,300
Avg volume
461,592
Day's range
$0.37 – $0.39
Shares out
8,888,000
Stochastic %K
16%
Beta
4.93
Analysts
—
Price target
$40.00

Price

Company profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hos...

Show more

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
972 3 541 3131
Website
https://www.redhillbio.com
Address
21 Ha’arba’a Street, Tel Aviv-Yafo, Israel

Latest news

Stocktwits

jv39 Nov 2, 8:34 PM
$RDHL Good news no volume.
0 replies
Pennyrocketsabc Nov 2, 2:49 PM
$RDHL watch could pop
0 replies
Henry20feb_ Oct 26, 7:21 PM
$RDHL Hyloris reports that it has more than 30 products and candidates competing for capital and management attention. Management explains that it has begun concentrating resources on programs with clearer prospects for regulatory approval, commercial launches and recurring income. Hyloris is not operating with unlimited resources. more significantly, the company decided in September 2026 to discontinue two other development programs and stop the XTRAZA Phase 3 trial and further U.S. development.
0 replies
Henry20feb_ Oct 26, 7:07 PM
$RDHL Hyloris pays the $200.000 termination fee (not the other way around).
0 replies
Nuisance Oct 23, 11:10 AM
$RDHL 🔥🔥🔥 https://www.stocktitan.net/sec-filings/RDHL/6-k-red-hill-biopharma-ltd-current-report-foreign-issuer-f5d88d70264f.html
0 replies
Patrick2343 Oct 22, 10:25 PM
$RDHL Wow looks like they continue to dilute on steroids.
0 replies
hanswilhelm Oct 21, 11:51 AM
$RDHL any day now 🥱
0 replies
Zaksab Oct 20, 7:24 PM
$RDHL Should I back Zuckerberg, Musk or Ben-Asher? All cost me the same in terms of transaction fee…
0 replies